Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CXXC-type zinc finger protein 5 (CXXC5) is a transcription factor involved in various developmental processes, including myelopoiesis, endothelial differentiation, and oligodendrocyte differentiation. It acts as a negative regulator of the Wnt/β-catenin signaling pathway by interacting with Dishevelled (Dvl). Dysregulation of CXXC5 is associated with diseases like osteoporosis, alopecia, and impaired wound healing. It binds to unmethylated CpG dinucleotides via its CXXC domain, influencing epigenetic regulation. Recent studies implicate it in breast carcinogenesis.
Negative regulation of Wnt/β-catenin signaling via Dvl binding; DNA binding to unmethylated CpG dinucleotides
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CXXC-type zinc finger protein 5 (CXXC5).